Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.20%99 Revenue per Share is $11.07 as of Jun. 2026. GuruFocus rates LMAT with a GF Score™ of 99/100 and a GF Value™ of $95.52 (Modestly Undervalued). Among 759 Medical Devices & Instruments companies, LeMaitre Vascular ranks better than 75.49% on this metric.
LeMaitre Vascular's revenue per share for the
three
months ended in Jun. 2026 was $2.87.
LeMaitre Vascular's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $11.07.
Good Sign:
LeMaitre Vascular Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue Per Share Growth Rate of LeMaitre Vascular was 8.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 14.30% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 11.40% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 9.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for LeMaitre Vascular's Revenue per Share or its related term are showing as below:
LMAT'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.9 Med: 7.2 Max: 21.4
Current: 14.3
During the past 13 years, LeMaitre Vascular's highest 3-Year average Revenue Per Share Growth Rate was 21.40% per year. The lowest was -4.90% per year. And the median was 7.20% per year.
LMAT's 3-Year Revenue Growth Rate is ranked better than 75.49% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 3.7
vs LMAT: 14.30
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
LeMaitre Vascular Revenue per Share Related Terms
LeMaitre Vascular Revenue per Share Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LMAT vs BLFS, KMTS, XRAY: Revenue per Share Comparison
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's PS Ratio distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
LeMaitre Vascular's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular (LMAT) has a Revenue per Share of $11.07 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on LeMaitre Vascular and its competitors. According to the industry distribution chart, LeMaitre Vascular ranks #186 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 24.5%.
Is LeMaitre Vascular's Revenue per Share too high?
LeMaitre Vascular's current Revenue per Share is $11.07. The Medical Devices & Instruments industry median Revenue per Share is 3.70. LeMaitre Vascular's value of $11.07 is 199.2% above this industry median. Based on the distribution chart, LeMaitre Vascular ranks #186 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, LeMaitre Vascular has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Revenue per Share compare to BLFS and KMTS?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #186 out of 759 companies for Revenue per Share. This places LeMaitre Vascular in the top 25% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.70. LeMaitre Vascular's value of $11.07 is 199.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.70, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current Revenue per Share of $11.07 is 199.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current Revenue per Share is $11.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.52, compared to a current price of $80.68 — trading 15.5% below its estimated fair value. The current Revenue per Share is $11.07 and 199.2% above the Medical Devices & Instruments industry median of 3.70. LeMaitre Vascular's overall GF Score™ is 99/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current Revenue per Share is $11.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $80.68 is trading 15.5% below its estimated GF Value™ of $95.52.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
Revenue per Share: $11.07
GF Value™: $95.52 vs. price of $80.68 (15.5% below fair value)
Industry Position: 199.2% above the Medical Devices & Instruments median (#186 of 759)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
99GF Score
Get the complete analysis for LMAT
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
